India's revised Schedule M and alignment with ICH Q7 have raised the compliance bar for API manufacturers. Here's what pharmaceutical buyers and suppliers need to know in 2025.
Why GMP Compliance Is Top of Mind in 2025
Good Manufacturing Practice (GMP) requirements for API manufacturers in India have undergone significant tightening over the past two years. The revised Schedule M (notified by the Ministry of Health and Family Welfare) and India's progressive alignment with ICH Q7 guidelines have elevated baseline expectations — and the consequences of non-compliance are more severe than ever.
For pharmaceutical manufacturers sourcing APIs, and for distributors supplying them, understanding the current compliance landscape is essential for avoiding supply disruptions and regulatory risk.
What Changed Under the Revised Schedule M
The revised Schedule M, which came into effect for large manufacturers in 2024 and is being extended to medium and small manufacturers through 2025, introduces:
1. Risk-Based Quality Systems
Manufacturers are now required to implement formal Pharmaceutical Quality Systems (PQS) aligned with ICH Q10 — moving from a documentation-first approach to a risk-management-first approach. This means written quality risk assessments for every critical process parameter.
2. Stricter Deviation and CAPA Management
Every production deviation must be formally documented, risk-classified, and closed with a verified Corrective and Preventive Action (CAPA). Trend analysis of deviations is now expected during inspections.
3. Enhanced Change Control
Any change to a manufacturing process, equipment, or starting material now requires a formal change control procedure with impact assessment on product quality and regulatory filings.
4. Data Integrity Requirements
This has been the biggest area of inspection findings globally. Revised Schedule M explicitly addresses:
- Audit trails in all computerised systems
- Prohibition of data deletion or backdating
- Second-person verification of critical entries
- Backup and disaster recovery procedures
5. Supplier Qualification
API manufacturers are now required to formally qualify their key starting material (KSM) and reagent suppliers — with site audits or questionnaire-based assessments, and documented approval processes.
Impact on API Distributors and Buyers
Documentation Expectations Have Risen
Formulation companies sourcing APIs now routinely request:
- Batch Manufacturing Records (BMR) summaries
- Process Validation reports for new batches
- Annual Product Reviews (APRs)
- Stability data for each storage condition
A distributor unable to facilitate these requests from manufacturers is increasingly uncompetitive.
Approved Vendor List (AVL) Requirements
Pharmaceutical manufacturers are required to source APIs only from their Approved Vendor Lists. This means distributors must help buyers complete vendor qualification audits — providing manufacturer GMP certificates, site master files, and audit reports.
ICH Q7 Alignment: What It Means Practically
ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) is the internationally harmonised GMP standard. India's alignment means:
| Requirement | Practical Implication |
|---|---|
| Critical Quality Attributes (CQAs) defined | Suppliers must declare CQAs in CoA |
| In-process controls documented | Process parameters reported per batch |
| Impurity profiling required | All known and unknown impurities below threshold |
| Reprocessing restrictions | Reprocessed batches require separate disclosure |
What Buyers Should Verify in 2025
When qualifying an API supplier today, verify:
- Valid WHO-GMP or Schedule M (revised) certificate — check expiry date
- CDSCO-approved manufacturing site for the specific API
- Recent (within 3 years) regulatory inspection report or customer audit
- Data integrity policy statement
- Electronic audit trail capability
Chennai Drugs and Chemicals' Approach
We source exclusively from manufacturers with current, valid GMP certifications and maintain updated regulatory files for all products in our portfolio. Every batch is supplied with a full documentation set: CoA, CoO, MSDS, and stability data on request — in line with revised Schedule M and ICH Q7 expectations.
Conclusion
GMP compliance in India is evolving rapidly, and 2025 marks a critical inflection point with Schedule M full implementation. Buyers should treat compliance verification as a routine procurement step, not a one-time exercise. Partner with distributors who understand these requirements and can provide the documentation infrastructure to support your quality system.